

Alteplase

S

Various toxicities: 4 case reports

In a multicenter, retrospective, observational study, conducted between 1 March 2020 and 3 March 2021, involving 102 patients, four patients [*ages and sexes not stated*] were described, who developed haematuria, gastrointestinal haemorrhage, haemoptysis, and intracranial haemorrhage following treatment with alteplase [*dosage and route not stated*]. The patients, who had severe acute respiratory failure secondary to COVID-19 infection and required mechanical ventilation received treatment with alteplase [Activase]. However, the patients developed haematuria (n=1), gastrointestinal haemorrhage (n=1), haemoptysis (n=1) and intracranial haemorrhage which resulted in death (n=1), secondary to alteplase.

Barrett CD, et al. Multicenter Study of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study. *Research and Practice in Thrombosis and Haemostasis* 6: No. 2, Feb 2022. Available from: URL: <http://doi.org/10.1002/rth2.12669>

803661145